1. Virologic and immunologic characterization of COVID-19 recrudescence after Nirmatrelvir/Ritonavir treatment;Carlin;Clin Infect Dis,2022
2. Characterization of virologic rebound following nirmatrelvir-ritonavir treatment for COVID-19;Boucau;Clin Infect Dis,2022
3. Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19;Hammond;N Engl J Med,2022
4. Epidemiology of infections with SARS-CoV-2 Omicron BA.2 variant in Hong Kong, January–March 2022;Mefsin;medRxiv [Preprint],2022